PLSE vs. PRCT, NVST, IRTC, NVCR, LIVN, ENOV, WRBY, TNDM, LMAT, and CNMD
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), Tandem Diabetes Care (TNDM), LeMaitre Vascular (LMAT), and CONMED (CNMD). These companies are all part of the "medical equipment" industry.
Pulse Biosciences vs.
PROCEPT BioRobotics (NASDAQ:PRCT) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.
Pulse Biosciences has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -50.07%. PROCEPT BioRobotics' return on equity of -38.57% beat Pulse Biosciences' return on equity.
89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 71.5% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
PROCEPT BioRobotics presently has a consensus price target of $97.86, suggesting a potential upside of 42.79%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Pulse Biosciences.
Pulse Biosciences received 209 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 67.86% of users gave PROCEPT BioRobotics an outperform vote while only 63.66% of users gave Pulse Biosciences an outperform vote.
Pulse Biosciences has lower revenue, but higher earnings than PROCEPT BioRobotics.
In the previous week, PROCEPT BioRobotics had 6 more articles in the media than Pulse Biosciences. MarketBeat recorded 9 mentions for PROCEPT BioRobotics and 3 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.90 beat PROCEPT BioRobotics' score of 0.72 indicating that Pulse Biosciences is being referred to more favorably in the news media.
PROCEPT BioRobotics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.
Summary
PROCEPT BioRobotics beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:PLSE) was last updated on 1/23/2025 by MarketBeat.com Staff
